NCT05156229View on ClinicalTrials.gov

A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 6, 2021

Primary Completion Date

August 24, 2022

Study Completion Date

August 24, 2022

Conditions
Cutaneous T-cell Lymphoma (CTCL)
Interventions
BIOLOGICAL

CDK-003

CDK-003 administered subcutaneously

Trial Locations (4)

B15 2TH

University Hospital Birmingham, Birmingham

G12 0YN

Beatson West of Scotland Cancer Centre Haematology, Glasgow

SE1 9RT

Guys Hospital/ Guy's Cancer Centre, London

M20 4BX

The Christie, Manchester

Sponsors

Lead Sponsor

Codiak BioSciences
All Listed Sponsors
lead

Codiak BioSciences

INDUSTRY